bs-4542R [Primary Antibody]
BRLF1 Polyclonal Antibody
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: BRLF1

Immunogen Range: 81-180/605


Clonality: Polyclonal

Isotype: IgG

Entrez Gene: 3783727

Swiss Prot: P03209

Source: KLH conjugated synthetic peptide derived from Epstein-Barr virus Replication and transcription activator

Purification: Purified by Protein A.

Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles.

Background:

Immediate-early transcription factor that controls the initiation of viral lytic gene expression and lytic reactivation from latency. Triggers lytic replication, and initiates a cellular senescence program in epithelial cells. Upregulates human DCR3/TNFRSF6B by directly binding to its receptor.

Size: 100ul

Concentration: 1ug/ul

Applications: WB(WB=1:500-2000)
ELISA(ELISA=1:5000-10000)
IHC-P(IHC-P=1:100-500)
IHC-F(IHC-F=1:100-500)
IF(IF=1:100-500)

Predicted Molecular Weight: 66.5


Cross Reactive Species: Human
Virus
(HHV4tp2)

For research use only. Not intended for diagnostic or therapeutic use.

PRODUCT SPECIFIC PUBLICATIONS
  • Hui D et al. CD44+CD24-/low sphere-forming cells of EBV-associated gastric carcinomas show immunosuppressive effects and induce Tregs partially through production of PGE2. Exp Cell Res. 2020 May 15;390(2):111968.Read more>>
  • Ruo-Wen Xiao. et al. Rare POLN mutations confer risk for familial nasopharyngeal carcinoma through weakened Epstein-Barr virus lytic replication. EBIOMEDICINE. 2022 Oct;84:104267Read more>>
VALIDATION IMAGES

Formalin-fixed and paraffin embedded human colon carcinoma labeled with Anti-BRLF1 Polyclonal Antibody, Unconjugated (bs-4542R) at 1:200 followed by conjugation to the secondary antibody and DAB staining.


Formalin-fixed and paraffin embedded human lung carcinoma labeled with Anti-BRLF1 Polyclonal Antibody, Unconjugated (bs-4542R) at 1:200 followed by conjugation to the secondary antibody and DAB staining.